GHK (Glycyl-L-Histidyl-L-Lysine)

1. Overview

GHK (glycyl-L-histidyl-L-lysine) is a naturally occurring human tripeptide with a molecular weight of 341.40 g/mol, first discovered by Loren Pickart and Marguerite Thaler in 1973 [1]. Working with human plasma fractions, Pickart observed that a factor isolated from young human serum (ages 20-25) could cause aged human liver tissue to synthesize proteins in a pattern resembling that of younger tissue. This factor was subsequently identified as the tripeptide glycine-histidine-lysine [1].

While GHK is most widely known in its copper-bound form, GHK-Cu (Copper Tripeptide-1), the free peptide itself is a distinct molecular entity with biological significance that has been increasingly recognized. GHK possesses a very high affinity for copper(II) ions (log K = 16.44), and in human plasma at physiological copper concentrations, the majority of GHK exists in the copper-bound state [6][7]. However, emerging research -- particularly gene expression studies using the Broad Institute Connectivity Map -- has demonstrated that GHK itself, independent of copper binding, modulates the expression of over 4,000 human genes across fundamental regulatory pathways [5].

GHK is present in human plasma, saliva, and urine. Plasma concentrations have been measured at approximately 200 ng/mL in individuals around age 20, declining to approximately 80 ng/mL by age 60 -- a decline of roughly 60% [6][7]. This age-related decrease has led to the hypothesis that diminishing GHK/GHK-Cu levels may contribute to the reduced regenerative capacity, increased inflammation, and accumulated tissue damage observed in aging [7][16].

The cosmetic ingredient nomenclature (INCI) designates the copper-free form as Tripeptide-1 and the copper-bound form as Copper Tripeptide-1. Both forms are widely used in topical skincare formulations. GHK is also the parent tripeptide from which several derivative peptides have been developed, including biotinoyl tripeptide-1 (biotin-conjugated GHK) and the structurally related AHK-Cu (alanyl-histidyl-lysine copper complex) [6].

Molecular Weight

341.40 g/mol (free peptide, without copper)

Molecular Formula

C14H24N6O4

Sequence

Gly-His-Lys

CAS Number

49557-75-7

Natural Occurrence

Human plasma (~200 ng/mL at age 20, declining to ~80 ng/mL by age 60)

Copper Affinity

High (log K = 16.44 for Cu2+)

Routes Studied

Topical, subcutaneous injection (as GHK-Cu)

INCI Name

Tripeptide-1 (copper-free); Copper Tripeptide-1 (with copper)

FDA Status

Not approved as drug; available as cosmetic ingredient

2. Mechanism of Action

GHK operates through multiple, interconnected mechanisms that distinguish it from single-target pharmacological agents. Its actions can be categorized into copper-dependent and copper-independent pathways.

Copper Binding and Delivery

GHK's high-affinity copper(II) binding (log K = 16.44) enables it to function as a biological copper transport molecule [6][7]. Copper is an essential cofactor for numerous enzymes critical to tissue repair and homeostasis, including:

• Lysyl oxidase -- essential for collagen and elastin cross-linking
• Superoxide dismutase (SOD) -- primary antioxidant defense enzyme
• Cytochrome c oxidase -- mitochondrial electron transport and cellular respiration
• Tyrosinase -- melanin synthesis

By delivering copper to cells and tissues, GHK supports the activity of these copper-dependent enzymes. The peptide's role as a copper shuttle has been proposed as a fundamental mechanism linking copper homeostasis to tissue repair and regeneration [7][16].

Gene Expression Modulation

The most significant recent advance in understanding GHK biology comes from large-scale gene expression analyses using the Broad Institute Connectivity Map, a publicly available database of transcriptional responses to bioactive compounds [5][18].

Pickart et al. (2012) used this tool to determine that GHK modulates the expression of 4,048 human genes -- approximately 31.2% of the human genome [5]. This extraordinarily broad effect profile includes:

• Tissue remodeling genes (upregulated) -- collagens, fibronectin, elastin, integrins
• Antioxidant defense genes (upregulated) -- SOD, catalase, glutathione-related enzymes [15]
• Anti-inflammatory genes (modulated) -- downregulation of IL-6, TNF-alpha, NF-kB pathway components
• DNA repair genes (upregulated) -- BRCA1, ATM, and other DNA damage response genes [5][17]
• Ubiquitin-proteasome genes (modulated) -- protein quality control and degradation pathways
• Nervous system genes (modulated) -- neuroprotective and synaptic function genes [10]

The breadth of gene expression changes suggests that GHK acts through fundamental regulatory pathways -- possibly epigenetic mechanisms or master transcriptional regulators -- rather than through a single receptor-mediated signaling cascade [5][7].

Extracellular Matrix Remodeling

GHK (primarily studied as GHK-Cu) stimulates synthesis and organization of key ECM components [2][3][4]:

• Collagen types I and III -- the primary structural proteins of dermis and connective tissue
• Decorin -- a small leucine-rich proteoglycan that regulates collagen fibril formation
• Dermatan sulfate and chondroitin sulfate -- glycosaminoglycans essential for tissue hydration
• Glycosaminoglycans -- including hyaluronic acid for tissue volume and elasticity

Simultaneously, GHK modulates the balance between matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), facilitating controlled tissue remodeling rather than simply increasing ECM deposition [4][14].

Anti-Inflammatory Activity

GHK suppresses expression of pro-inflammatory cytokines including IL-6 and TNF-alpha in multiple experimental systems [6][7]. Gene expression analyses reveal downregulation of NF-kB pathway components, suggesting inhibition of a central inflammatory signaling hub [5].

Stem Cell and Integrin Regulation

GHK-Cu has been shown to increase integrin expression and p63 positivity in keratinocytes, indicating enhanced stemness properties and cell adhesion capacity [19]. This may contribute to the peptide's ability to support tissue regeneration and wound healing.

3. Researched Applications

Wound Healing and Tissue Repair

Evidence level: Moderate (in vivo animal studies, clinical data for GHK-Cu)

GHK was among the first matrikines -- ECM-derived peptide fragments that regulate cell behavior -- to be characterized for wound healing [4]. Maquart et al. (1993) demonstrated that GHK-Cu in collagen sponges significantly increased collagen synthesis, glycosaminoglycan production, and DNA synthesis in rat wound models [3]. Canapp et al. (2003) confirmed faster wound healing, increased tensile strength, and higher collagen content in a canine wound model [13]. Simeon et al. (2000) further showed that GHK-Cu stimulated integrin expression and fibroblast proliferation in wound tissue [14].

Skin Anti-Aging and Photoprotection

Evidence level: Moderate (controlled human trials for GHK-Cu formulations)

Topical GHK-Cu has been studied in several controlled clinical trials for skin rejuvenation. Leyden et al. (2002) demonstrated improved skin laxity, clarity, firmness, and reduced fine lines in 67 women aged 41-62 after 12 weeks of GHK-Cu cream application [11]. Abdulghani et al. (1998) reported improved skin appearance and increased dermal thickness in photodamaged skin [12]. These effects are attributed to stimulation of collagen and glycosaminoglycan synthesis by dermal fibroblasts [6].

COPD and Lung Tissue Remodeling

Evidence level: Preliminary (bioinformatics/in silico)

In a landmark bioinformatics study, Campbell et al. (2012) analyzed gene expression signatures of emphysematous lung tissue from COPD patients and searched the Connectivity Map for compounds that could reverse the pathological pattern [8]. Among 1,309 compounds tested, GHK emerged as the top candidate, capable of reversing the destructive gene expression signature toward a pattern of healthy tissue remodeling [8]. This finding suggests potential therapeutic relevance in COPD, though no clinical studies have been conducted.

Anti-Cancer Gene Expression

Evidence level: Preliminary (bioinformatics/in silico)

Hong et al. (2010) identified a 54-gene signature associated with aggressive, metastatic colon cancer [9]. Using the Connectivity Map, GHK at 1 micromolar concentration was found to reverse the differential expression of 70% of these genes, shifting the pattern from pro-metastatic to a less aggressive expression profile [9]. Additional analyses by Pickart (2014) showed that GHK upregulated 10 caspase and caspase-associated genes and modulated 84 DNA repair genes [17]. These computational findings suggest anti-cancer potential but require experimental validation.

Neuroprotection and Cognitive Function

Evidence level: Preliminary (bioinformatics/in silico)

Gene expression analysis by Pickart (2017) revealed that GHK modulates genes relevant to nervous system function and cognitive decline, including upregulation of neuroprotective genes and downregulation of neuroinflammatory pathways [10]. This remains a speculative area without clinical or preclinical experimental data.

Antioxidant Defense

Evidence level: Preliminary (bioinformatics/in silico)

GHK modulates numerous genes involved in antioxidant defense, including those encoding SOD, catalase, and glutathione-related enzymes [15]. This suggests a role in protecting tissues from oxidative stress beyond the direct copper-dependent activation of SOD.

4. Clinical Evidence Summary

Clinical evidence for GHK is most developed for the copper-bound form (GHK-Cu) in topical skin applications. For the copper-free peptide, evidence for gene expression modulation comes primarily from bioinformatics analyses. No clinical trials have specifically evaluated GHK without copper.

5. Dosing in Research

GHK has been studied primarily in its copper-bound form (GHK-Cu) for topical applications. The gene expression data are derived from computational analyses at reference concentrations. The following reflects doses reported in published research.

6. Safety and Side Effects

GHK has a favorable safety profile consistent with its nature as a naturally occurring human peptide present in plasma at physiological concentrations [6][7].

Topical safety: Clinical trials of GHK-Cu creams and serums report good tolerability with no serious adverse events [11][12]. Mild skin irritation has been observed in some users of copper peptide products, though this may relate to the formulation base rather than the peptide itself.

Systemic safety: Safety data for injectable GHK or GHK-Cu in humans are limited. Animal studies using subcutaneous injection in wound models did not report adverse effects [3][13].

Copper considerations: While GHK's copper-binding capacity is integral to many of its functions, excessive copper supplementation carries theoretical risks of oxidative stress. Individuals with Wilson disease or other copper metabolism disorders should exercise caution with copper-containing formulations [7].

Gene expression effects: The extremely broad gene expression modulation (over 4,000 genes) observed in bioinformatics studies raises theoretical questions about unintended effects of systemic administration at pharmacological concentrations. However, GHK is present naturally in human plasma, and no adverse effects have been attributed to physiological concentrations [5][7].

Endogenous decline: The natural decline in GHK/GHK-Cu plasma levels with aging (from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60) suggests that exogenous supplementation within physiological ranges is unlikely to produce adverse effects [6].

7. Regulatory Status

Cosmetic ingredient: GHK (as Tripeptide-1) and GHK-Cu (as Copper Tripeptide-1) are listed in the International Nomenclature of Cosmetic Ingredients (INCI) and are widely available in topical skincare and haircare formulations without pharmaceutical regulation.

FDA: Not approved as a drug for any indication. Topical cosmetic use is not subject to pre-market drug approval.

Injectable use: Injectable GHK or GHK-Cu is not approved for human use in any regulatory jurisdiction.

US Compounding Status (2026): On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that GHK-Cu would be reclassified from Category 2 to Category 1 on the FDA bulk drug substance list, restoring legal compounding access with a physician prescription. The formal Federal Register publication is pending as of March 2026.

WADA: Not specifically listed on the World Anti-Doping Agency prohibited substance list.

8. Pharmacokinetics

GHK pharmacokinetics are characterized by its nature as a very small endogenous tripeptide (341.40 Da) with rapid turnover in biological fluids [6][7][16].

Plasma levels and age-related decline. GHK circulates in human plasma at approximately 200 ng/mL (approximately 0.6 micromolar) in individuals around age 20, declining to approximately 80 ng/mL (approximately 0.23 micromolar) by age 60 -- a 60% reduction over four decades [6][7]. This age-related decline parallels the progressive loss of regenerative capacity, increased inflammatory burden, and accumulated tissue damage associated with aging, leading to the hypothesis that diminishing GHK levels contribute directly to age-related tissue degeneration [7][16].

Plasma half-life. As a free tripeptide, GHK has a very short plasma half-life estimated at minutes. Small peptides are rapidly degraded by circulating and membrane-bound aminopeptidases, dipeptidyl peptidases, and other serum proteases. The short half-life limits systemic bioavailability following topical application and necessitates frequent dosing or sustained-release formulation strategies for systemic applications [6][7].

Copper equilibrium. In human plasma at physiological copper concentrations (approximately 10-20 micromolar total copper), the majority of GHK exists in the copper-bound form (GHK-Cu) due to its high copper(II) affinity (log K = 16.44) [6][7]. This copper complexation may protect the peptide from certain proteolytic cleavage mechanisms, potentially extending the effective half-life of the GHK-Cu complex relative to the copper-free peptide.

Topical penetration. GHK-Cu in topical formulations (creams, serums) penetrates the stratum corneum and reaches the dermal layer, as evidenced by its documented effects on dermal fibroblast collagen synthesis and skin thickness in clinical trials [11][12]. The small molecular weight (approximately 403 Da with copper) is below the 500 Da cutoff generally considered favorable for skin penetration. Liposomal formulations, as used in the Canapp et al. (2003) canine wound study, may enhance dermal delivery and bioavailability at the wound site [13].

Renal clearance. GHK and its metabolic fragments are cleared by the kidneys. No formal renal pharmacokinetic studies have been published. Renal impairment may slow clearance of the peptide, but clinical implications are unknown given that GHK is an endogenous molecule.

Source of endogenous GHK. Plasma GHK is generated through the proteolytic degradation of collagen type I and other extracellular matrix proteins. As a matrikine, GHK represents an ECM-derived fragment that provides feedback signaling from tissue remodeling to cells in the local and systemic environment [4][6]. The decline in plasma GHK with aging likely reflects decreased ECM turnover, reduced collagen content, and altered protease activity in aging tissues.

9. Dose-Response Relationships

GHK demonstrates dose-dependent effects across multiple experimental systems, though most dose-response data derive from in vitro and in silico analyses rather than clinical trials [5][6][7].

Gene expression dose-response (Connectivity Map). The Broad Institute Connectivity Map analysis by Pickart et al. (2012) used a reference concentration of 1 micromolar GHK, at which the peptide modulated expression of 4,048 human genes (approximately 31.2% of the genome) [5]. This concentration is within the physiological range seen in young plasma (approximately 0.6 micromolar), suggesting that gene expression effects occur at biologically relevant concentrations. Dose-response studies at multiple GHK concentrations in the Connectivity Map framework have not been published, leaving uncertainty about whether the gene expression profile changes qualitatively or only quantitatively at different concentrations.

Collagen synthesis dose-response. Maquart et al. (1988, 1993) demonstrated concentration-dependent stimulation of collagen synthesis by GHK-Cu in fibroblast cultures and in rat wound models [2][3]. Optimal collagen stimulation was observed at concentrations in the nanomolar to low micromolar range. At very high concentrations, GHK-Cu may exhibit biphasic behavior, a pattern common to growth factor-like molecules.

In vivo wound healing dose-response. In the Maquart et al. (1993) rat wound model, GHK-Cu at 0.5 mcg per injection site in collagen sponges significantly increased collagen synthesis, glycosaminoglycan production, and DNA synthesis [3]. Dose-response across a wider concentration range has not been systematically explored in vivo.

Anti-cancer gene expression. Hong et al. (2010) demonstrated that GHK at 1 micromolar reversed the differential expression of 70% of the 54 genes in a metastatic colon cancer signature [9]. Whether lower or higher concentrations produce proportionally different effects remains unknown.

Clinical topical dose-response. In the Leyden et al. (2002) clinical trial, GHK-Cu cream was applied twice daily for 12 weeks [11]. No dose-ranging was performed across different GHK-Cu concentrations, so the clinical dose-response for topical skin remodeling remains undefined. Commercially available GHK-Cu products typically contain 0.01-0.1% copper peptide, but optimal clinical concentrations have not been established through comparative dose-response studies.

10. Comparative Effectiveness

GHK vs. GHK-Cu

GHK (copper-free, Tripeptide-1) and GHK-Cu (copper-bound, Copper Tripeptide-1) are often conflated but represent distinct molecular entities with overlapping but not identical activities [6][7]. Most biological studies have evaluated GHK-Cu rather than GHK alone. The copper-bound form provides both copper delivery (supporting lysyl oxidase, SOD, and cytochrome c oxidase activity) and the peptide-mediated signaling effects. The copper-free form retains gene expression modulatory activity, as demonstrated by the Connectivity Map analyses, but lacks the copper delivery function [5][7]. For topical skin applications, GHK-Cu is generally preferred due to its dual mechanism. For gene expression-mediated effects (COPD, anti-cancer), the available data cannot distinguish whether copper is essential because the Connectivity Map analyses used the peptide alone [5][8][9].

GHK-Cu vs. Retinoids (Tretinoin/Retinol)

Tretinoin is the gold standard topical anti-aging treatment with extensive controlled trial data demonstrating improvement in fine lines, hyperpigmentation, and collagen synthesis. In the Abdulghani et al. (1998) study, GHK-Cu formulations improved skin appearance and thickness in photodamaged skin, but direct head-to-head comparison with tretinoin within the same trial showed tretinoin producing superior improvements in some parameters [12]. GHK-Cu has the advantage of better tolerability (no irritation, dryness, or photosensitivity), while tretinoin has the advantage of a much larger evidence base and established dose-response across multiple concentrations.

GHK-Cu vs. Vitamin C (Ascorbic Acid)

In the Leyden et al. (2002) study, GHK-Cu cream was directly compared to a vitamin C-containing cream and placebo [11]. GHK-Cu outperformed both vitamin C and placebo for skin laxity, clarity, and firmness over 12 weeks. Both GHK-Cu and vitamin C stimulate collagen synthesis, but through different mechanisms: GHK-Cu acts through copper delivery and matrikine signaling, while vitamin C acts as an essential cofactor for prolyl and lysyl hydroxylases in collagen post-translational modification.

GHK vs. Matrixyl (Palmitoyl Pentapeptide-4)

Both GHK and Matrixyl are matrikine peptides that stimulate ECM synthesis. Matrixyl has been evaluated in several controlled clinical studies for anti-wrinkle efficacy, with documented improvements in skin roughness and wrinkle depth. No direct head-to-head comparison between GHK-Cu and Matrixyl has been published. They have complementary mechanisms: GHK acts through copper delivery and broad gene expression modulation, while Matrixyl mimics collagen fragments that signal through TGF-beta-dependent pathways.

| Feature | GHK-Cu | Tretinoin | Vitamin C | Matrixyl | |---|---|---|---|---| | Evidence level | Moderate (RCTs) | Strong (extensive RCTs) | Moderate | Moderate | | Collagen stimulation | Yes | Yes | Yes (cofactor) | Yes | | Gene expression modulation | Over 4,000 genes | Broad RAR/RXR-mediated | Limited | Limited | | Copper delivery | Yes | No | No | No | | Tolerability | Excellent | Irritation common | Good | Excellent | | Photosensitivity risk | No | Yes | No | No |

11. Enhanced Safety Profile

GHK has an exceptionally favorable safety profile consistent with its status as a naturally occurring human peptide present in plasma throughout life [6][7].

Endogenous safety margin. GHK circulates at measurable concentrations in all healthy individuals (approximately 80-200 ng/mL depending on age), providing inherent evidence of safety at physiological concentrations [6]. The age-related decline in GHK suggests that exogenous supplementation to restore youthful levels (approximately 200 ng/mL) operates within the bounds of normal human physiology.

Clinical trial safety. In the Leyden et al. (2002) trial involving 67 women applying GHK-Cu cream twice daily for 12 weeks, no serious adverse events were reported [11]. The Abdulghani et al. (1998) study of 40 subjects over 12 weeks similarly reported good tolerability [12]. No allergic contact dermatitis, photosensitivity, or systemic effects have been documented in published clinical studies.

Wound healing studies. In animal wound healing studies, subcutaneous injection of GHK-Cu in collagen sponges and topical liposomal GHK-Cu produced no adverse effects beyond the expected wound healing response [3][13][14]. The canine wound study by Canapp et al. (2003) reported faster healing with increased tensile strength and no adverse tissue reactions [13].

Copper toxicity considerations. GHK-Cu delivers copper ions to tissues, raising theoretical concerns about copper-mediated oxidative stress at supraphysiological concentrations [7]. However, GHK paradoxically modulates antioxidant gene expression (upregulating SOD, catalase, and glutathione enzymes), potentially counteracting any pro-oxidant copper effects [15]. Individuals with Wilson disease or other copper metabolism disorders should avoid copper-containing formulations as a precaution.

Gene expression breadth. The modulation of over 4,000 genes by GHK at 1 micromolar raises theoretical questions about unintended effects of pharmacological-dose systemic administration [5]. However, these gene expression changes have been characterized as shifting patterns toward a healthier, younger profile rather than inducing novel or pathological gene expression. No adverse gene expression signatures have been identified in the Connectivity Map analyses.

Cosmetic use track record. GHK-Cu (Copper Tripeptide-1) has been marketed as a cosmetic ingredient for over two decades, with widespread use in topical skincare products globally. The absence of significant adverse event reports from cosmetic use over this extended period provides additional real-world safety evidence, though cosmetic products are not subject to formal post-marketing surveillance.

Pregnancy and pediatric safety. No specific safety data exist for GHK or GHK-Cu use during pregnancy, lactation, or in pediatric populations. As an endogenous molecule present in all age groups, topical use at cosmetic concentrations is unlikely to pose risk, but specific studies are lacking.

12. Related Peptides

See also: GHK-Cu, Biotinoyl Tripeptide-1, AHK-Cu, Collagen Peptides, Matrixyl

• GHK-Cu -- The copper-bound form of GHK, which is the most studied and commercially used derivative. Most wound healing and skin remodeling studies have used the copper complex rather than the free peptide.

• Biotinoyl Tripeptide-1 -- A biotin-conjugated derivative of GHK designed for hair care applications, combining the follicle-supportive properties of GHK with the keratin-supporting effects of biotin.

• AHK-Cu -- A structurally related copper tripeptide (Ala-His-Lys-Cu) where alanine replaces glycine at position 1, engineered for enhanced hair growth activity through dermal papilla cell stimulation.

• Matrixyl -- Another matrikine peptide (palmitoyl pentapeptide-4) that, like GHK, stimulates ECM synthesis and collagen production in skin, though through a different signaling pathway.

• Collagen Peptides -- Hydrolyzed collagen fragments that share with GHK the property of being ECM-derived bioactive peptides that can stimulate new collagen synthesis.

13. References

1. [1] Pickart L, Thaler MM. (1973). Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nature New Biology. DOI PubMed
2. [2] Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. (1988). Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. DOI PubMed
3. [3] Maquart FX, Bellon G, Chaqour B, Wegrowski J, Pira S, Gillery P, Monboisse JC, Borel JP. (1993). In vivo stimulation of connective tissue accumulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ in rat experimental wounds. Journal of Clinical Investigation. DOI PubMed
4. [4] Maquart FX, Simeon A, Pira S, Gillery P, Borel JP. (1999). Regulation of cell activity by the extracellular matrix: the concept of matrikines. Journal of the Society of Biology. PubMed
5. [5] Pickart L, Vasquez-Soltero JM, Margolina A. (2012). GHK and DNA: resetting the human genome to health. BioMed Research International. DOI PubMed
6. [6] Pickart L, Vasquez-Soltero JM, Margolina A. (2015). GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International. DOI PubMed
7. [7] Pickart L, Margolina A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. DOI PubMed
8. [8] Campbell JD, McDonough JE, Zeskind JE, Hackett TL, Pechkovsky DV, Brandsma CA, et al. (2012). A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK. Genome Medicine. DOI PubMed
9. [9] Hong Y, Downey T, Eu KW, Koh PK, Cheah PY. (2010). A metastasis-prone signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clinical and Experimental Metastasis. DOI PubMed
10. [10] Pickart L. (2017). The effect of the human peptide GHK on gene expression relevant to nervous system function and cognitive decline. Brain Sciences. DOI PubMed
11. [11] Leyden JJ, Stevens T, Finkey MB, Barkovic S. (2002). Skin care benefits of copper peptide containing facial cream. American Academy of Dermatology 60th Annual Meeting. PubMed
12. [12] Abdulghani AA, Sherr S, Shirin S, et al. (1998). Effects of topical creams containing vitamin C, a copper-binding peptide cream and melatonin compared with tretinoin on the ultrastructure of normal skin. Disease Management and Clinical Outcomes. PubMed
13. [13] Canapp SO, Farese JP, Schultz GS, et al. (2003). The effect of topical tripeptide-copper complex on healing of ischemic open wounds. Veterinary Surgery. DOI PubMed
14. [14] Simeon A, Wegrowski Y, Bontemps Y, Maquart FX. (2000). Expression of glycosaminoglycans and small proteoglycans in wounds: modulation by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu(2+). Journal of Investigative Dermatology. DOI PubMed
15. [15] Pickart L, Vasquez-Soltero JM, Margolina A. (2015). GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes. Cosmetics. DOI
16. [16] Pickart L. (2009). The human tripeptide GHK (glycyl-L-histidyl-L-lysine), the copper switch, and the treatment of the degenerative conditions of aging. Anti-Aging Therapeutics.
17. [17] Pickart L. (2014). GHK, the human skin remodeling peptide, induces anti-cancer expression of numerous caspase, growth regulatory, and DNA repair genes. Journal of Analytical Oncology.
18. [18] Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. (2006). The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. DOI PubMed
19. [19] Kang YA, Choi HR, Na JI, Huh CH, Kim MJ, Youn SW, Kim KH, Park KC. (2009). Copper-GHK increases integrin expression and p63 positivity by keratinocytes. Archives of Dermatological Research. DOI PubMed
20. [20] Pollard JD, Quan S, Kang T, Koch RJ. (2005). Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Archives of Facial Plastic Surgery. DOI PubMed